A 2014 TOP DOC
Dr. Bernie Chang is Director of Plastic & Reconstructive Surgery at Mercy and also leads The Breast Reconstruction and Restoration Center. He pioneered treatment options like DIEP flap breast reconstruction.
Expert gynecologic oncologists at Mercy guide women through diagnosis and treatment of ovarian cancer.
Named a Best Regional Hospital in Diabetes and Endocrinology by U.S. News and World Report, Mercy Medical Center is home to The Center for Endocrinology.
Dwight D. Im, M.D., FACOG, Director of The Gynecologic Oncology Center at Mercy and The National Institute of Robotic Surgery at Mercy in Baltimore, became the first surgeon in the world to successfully perform a minimally-invasive hysterectomy via robotic surgery using the new Single-Site Wristed Needle Driver, developed by Intuitive Surgical, Inc. (ISRG).
Mercy offers emergency care on the Downtown Baltimore campus 24 hours a day, 7 days a week (410-332-9477) with access to a trained emergency medicine team, diagnostic services and consultations with specialists.
In case of an Emergency, Dial 911 and follow the instructions of the EMS (Emergency Medical Services) team.
Mercy Medical Center's downtown campus includes our Main Hospital - The Mary Catherine Bunting Center, McAuley Plaza and The Weinberg Center.
General visiting hours at Mercy are 11:00 am to 8:30 pm. Hours vary by floor, please check with the nursing staff or call 410-332-9555.
Currently Displaying: Active Clinical Trials
The Aromatase Inhibitor Cardiovascular Health Evaluation (ACE) Study will examine the cardiovascular (heart) health of breast cancer patients during their first year of aromatase inhibitor (AI) treatment and determine whether AIs affect the cardiovascular health of African-American breast cancer patients differently than Caucasian breast cancer patients. This study is for women diagnosed with postmenopausal, early-stage (stages I and II) breast cancer who are initiating AI (Femara, Arimidex or Aromasin) treatment. Funded by Susan G. Komen for the Cure®.
The purpose of this phase II trial is to evaluate the efficacy and tolerability of oral veliparib, a PARP inhibitor, in subjects with BRCA1 or BRCA2 mutation and metastatic breast cancer. Subjects will be randomized to one of three treatment regimens: Veliparib in combination with Temozolomide (TMZ), Veliparib in combination with carboplatin and paclitaxel, or placebo in combination with carboplatin and paclitaxel. (AbbVie M12-895, ClinicalTrials.gov ID#: NCT01506609)
This is an observational study for those who are at high risk for febrile neutropenia with Stage I-III breast cancer.
This study is designed for patients desiring nipple reconstruction following surgery for breast cancer and breast reconstruction. Eligible patients will receive a surgical procedure to reconstruct one or both nipples utilizing the COOK® Biodesign® Plastic Surgery Matrix. The study is designed to evaluate the benefit of this device in achieving effective and aesthetic nipple reconstruction. Patients will be evaluated at the time of the procedure and at 1 week, 4 weeks, 3 months, 6 months, and 12 months after surgery to examine the projection of their reconstructed nipple(s) and patient satisfaction (Cook Medical Study 09-009; Clinicaltrials.gov ID#: NCT01216319).
This randomized phase III trial is studying how well giving hormone therapy together with or without everolimus works in treating patients with high-risk, hormone receptor-positive, HER2-negative breast cancer. (SWOG S1207, ClinicalTrials.gov ID#: NCT01674140)
This is a phase III trial comparing trastuzumab + pertuzumab + taxane following versus trastuzumab emtansine + pertuzumab, following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer. (Roche BO28407, ClinicalTrials.gov ID#: NCT01966471
This phase III study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab (also known as Herceptin®) as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. (Roche BO27938 / NSABP B-50-I / GBG 77, ClinicalTrials.gov ID#: NCT01772472)
The primary aim of the study is to determine the microbiological environment of the peritoneal tissues of patients undergoing cytoreductive surgery with intraoperative hyperthermic chemotherapy for appendix cancer with peritoneal spread.
This trial compares olaparib versus placebo as adjuvant treatment in patients with BRCA1 or BRCA2 mutations and triple negative breast cancer (ClinicalTrials.gov ID#: NCT02032823)
This is a prospective, observational study that will assess the impact of MammaPrint on treatment decisions (chemotherapy plus endocrine versus endocrine alone) in patients with an intermediate score by Oncotype DX®. MammaPrint is an FDA-cleared test that may be used to identify which early-stage breast cancer patients are at risk of distant recurrence following surgery. (Clinicaltrials.gov ID#: NCT01617954)
The purpose of this study is to compare the effect of adding the drug trastuzumab (also called Herceptin®) to breast radiation therapy versus radiation alone. Trastuzumab has been shown to block the HER2 protein and to slow down or stop the growth of HER2-postive “invasive” breast cancers. Radiation therapy is the standard treatment for patients with DCIS. (NSABP B-43, Clinicaltrials.gov ID#: NCT00769379)
The objective of this phase III clinical trial is to determine the effect of endocrine therapy with or without chemotherapy in patients with node-positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX®. (SWOG S1007, Clinicaltrials.gov ID#: NCT01272037)
This is an observational study for women who are receiving Intraoperative Radiation Therapy (IORT) following breast-conserving surgery. (ClinicalTrials.gov ID#: NCT01570998)
The clinical team of The Prevention & Research Center at Mercy Medical Center in Baltimore, Maryland, offers patients and their families cancer genetic counseling and testing as well as a number of distinctive cancer wellness programs to support cancer recovery and help families manage life after cancer treatment.